



US009828336B2

(12) **United States Patent**
Moniz et al.

(10) **Patent No.:** **US 9,828,336 B2**
(45) **Date of Patent:** **Nov. 28, 2017**

(54) **METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS**

(71) Applicant: **Eisai R&D Management Co., Ltd.**,
Tokyo (JP)

(72) Inventors: **George Anthony Moniz**, Cambridge, MA (US); **Annie Zhu Wilcoxon**, North Reading, MA (US); **Farid Benayoud**, North Andover, MA (US); **Toshiaki Tanaka**, Tsukuba (JP); **Keiichi Sorimachi**, Tsukuba (JP)

(73) Assignee: **Eisai R&D Management Co., Ltd.**,
Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/158,687**

(22) Filed: **May 19, 2016**

(65) **Prior Publication Data**

US 2016/0318858 A1 Nov. 3, 2016

Related U.S. Application Data

(62) Division of application No. 14/379,063, filed as application No. PCT/US2013/026204 on Feb. 14, 2013, now Pat. No. 9,416,109.

(60) Provisional application No. 61/600,109, filed on Feb. 17, 2012.

(51) **Int. Cl.**

C07C 309/73 (2006.01)
C07C 303/44 (2006.01)
C07C 309/66 (2006.01)
C07C 69/16 (2006.01)
C12P 7/22 (2006.01)
C07D 401/12 (2006.01)
C07D 239/34 (2006.01)
C07C 303/28 (2006.01)
C07C 29/147 (2006.01)

(52) **U.S. Cl.**

CPC **C07C 309/73** (2013.01); **C07C 29/147** (2013.01); **C07C 69/16** (2013.01); **C07C 303/28** (2013.01); **C07C 303/44** (2013.01); **C07C 309/66** (2013.01); **C07D 239/34** (2013.01); **C07D 401/12** (2013.01); **C12P 7/22** (2013.01); **C07B 2200/07** (2013.01); **C07C 2601/02** (2017.05)

(58) **Field of Classification Search**

CPC ... **C07C 309/73**; **C07C 303/44**; **C07C 309/66**;
C07C 69/16; **C07C 29/147**; **C07C 303/28**;
C07C 2101/02; **C12P 7/22**; **C07D 239/34**;

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,849,954 A 12/1998 Carpino et al.
8,268,848 B2 9/2012 Terauchi et al.
9,416,109 B2* 8/2016 Moniz C07C 309/73
2012/0095031 A1 4/2012 Terauchi et al.

FOREIGN PATENT DOCUMENTS

FR 2302994 A1 10/1976
FR 2941454 A1 7/2010
JP A-2010-509334 3/2010
WO WO 2008/057575 A2 5/2008
WO WO 2008/150364 A1 12/2008
WO WO 2010/032200 A1 3/2010
WO WO 2010/063662 A1 6/2010

OTHER PUBLICATIONS

Viout, P., "Formation of a cyclopropane ester on a polymer support: effect of the macromolecular backbone on the stereoselectivity of cyclization." *Journal of the Chemical Society, Perkin Transactions 1* (1984): 1351-1356.*

United States Patent and Trademark Office, Notice of Allowance, U.S. Appl. No. 14/379,063, dated Jan. 21, 2016, 7 pages.

State of Israel Justice Department Patents Authority, Notification before Allowance of Patent Application No. 232949, dated Jun. 22, 2016 (2 pages) and English translation (2 pages).

International Search Report and Written Opinion, PCT/US2013/026204, dated Apr. 25, 2013.

Valgimigli L et al. The effect of ring nitrogen atoms on the homolytic reactivity of phenolic compounds; understanding the radical-scavenging ability 5-pyrimidinols. *Chem Eur J.* Oct. 17, 2003; 9(20): 4997-5010.

Yamaguchi K et al. Construction of a cis-cyclopropane via reductive radical decarboxylation. Enantioselective synthesis of cis- and trans-1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents. *J Org Chem.* Jun. 11, 2003; 68(24): 9255-9262.

Banfi L et al. On the optimization of pig pancreatic lipase catalyzed monoacylation of prochiral diols. *Tetrahedron Asymmetry.* 1995; 6(6): 1345-1356.

Oger C et al. Lipase-Catalyzed Regioselective Monoacylation of Unsymmetrical 1,5-Primary Diols. *Journal of Organic Chemistry.* 2010; 75: 1892-1897.

Office Action, Singapore Patent Application No. 11201403216U, dated May 27, 2015.

Office Action, Chinese Patent Application No. 201380009575.3, dated Jun. 1, 2015.

Response to Office Action, Chinese Patent Application No. 201380009575.3, dated Oct. 15, 2015.

Response to Office Action, Singapore Patent Application No. 11201403216U, dated Oct. 27, 2015.

Office Action, Israeli Application No. 232949; dated Nov. 2, 2015. *Aldrich Chemfiles* 2007 7(2), Peptide Synthesis, copyright Sigma Aldrich Co., p. 1-20.

Office Action, U.S. Appl. No. 14/370,063, dated Mar. 11, 2015, 7 pp.

(Continued)

Primary Examiner — Matt Mauro

(74) *Attorney, Agent, or Firm* — Myers Bigel, P.A.

(57) **ABSTRACT**

The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.

(56)

References Cited

OTHER PUBLICATIONS

Office Action, U.S. Appl. No. 14/370,063, dated Jul. 24, 2015, 16 pp.

Response to Office Action, Israeli Application No. 232949 (Hebrew) (3 pages), filed Mar. 20, 2016, and English translation thereof (3 pages); Annex A (1 page); Annex B (1 page); Annex C (1 page); Claims (13 pages); specification (69 pages).

United States Patent and Trademark Office, Notice of Allowance, U.S. Appl. No. 14/379,063, dated May 12, 2016, 7 pages.

Patent Office of the People's Republic of China; Notification to Go Through Formalities of Registration, Notification to Grant Patent Right for Invention, Chinese Patent Application No. 201380009575.

3, dated May 24, 2016 (2 pages) and English translation (3 pages).

Notice of Allowance, Russian Patent Application No. 2014137470,

dated Feb. 1, 2017.

Xu F et al. Stereocontrolled synthesis of trisubstituted cyclopropanes: expedient, atom-economical, asymmetric syntheses of (+)-bicycladine and DOV21947. *Organic Letters*, 8(17), Jul. 25, 2006, 3885-3888.

Shuto S et al. Synthesis of conformationally restricted analogs of baclofen, a potent GABA(B) receptor agonist, by the introduction of a cyclopropane ring. *Chemical & Pharmaceutical Bulletin*, 47(8), 1999, 1188-1192.

Shuto S et al. Synthesis of (+) and (-)-milnaciprans and their conformationally restricted analogs. *Tetrahedron Letters*, 37(5), 1996, 641-644.

Kazuta Y et al. Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic moiety as novel NMDA receptor antagonists: the aromatic group is essential for the activity. *Bioorganic & Medicinal Chemistry*, 10, 2002, 3829-3848.

Office Action. Mexican Patent Application No. MX/z/2014/009917, dated May 24, 2017.

Response to Office Action, Mexican Patent Application No. MX/a/2014/009917, submitted to the Mexican Institute of Industrial Property dated Aug. 14, 2017.

European Patent Office Examination Report, EP 13706674.8, dated Oct. 6, 2017.

* cited by examiner

1

METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of and claims priority to U.S. patent application Ser. No. 14/379,063, filed Aug. 15, 2014, now allowed, which is a 35 U.S.C. §371 national phase entry of PCT Application PCT/US2013/026204, filed Feb. 14, 2013, and published in English on Aug. 22, 2013, as International Publication No. WO 2013/123240, and which claims the benefit of U.S. Provisional Patent Application No. 61/600,109, filed Feb. 17, 2012, the disclosure of each of which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION


The present invention relates to compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.

BACKGROUND OF THE INVENTION

Orexin receptors are G-protein coupled receptors found predominately in the brain. Their endogenous ligands, orexin-A and orexin-B, are expressed by neurons localized in the hypothalamus. Orexin-A is a 33 amino acid peptide; orexin-B consists of 28 amino acids. (Sakurai T. et al., Cell, 1998, 92, 573-585). There are two subtypes of orexin receptors, OX_1 and OX_2 ; OX_1 binds orexin-A preferentially, while OX_2 binds both orexin-A and -B. Orexins stimulate food consumption in rats, and it has been suggested that orexin signaling could play a role in a central feedback mechanism for regulating feeding behavior (Sakurai et al., supra). It has also been observed that orexins control wake-sleep conditions (Chemelli R. M. et al., Cell, 1999, 98, 437-451). Orexins may also play roles in brain changes associated with opioid and nicotine dependence (S. L. Borgland et al., Neuron, 2006, 49, 598-601; C. J. Winrow et al., Neuropharmacology, 2010, 58, 185-194), and ethanol dependence (J. R. Shoblock et al., Psychopharmacology, 2011, 215, 191-203). Orexins have additionally been suggested to play a role in some stress reactions (T. Ida et al., Biochem. Biophys. Res. Commun., 2000, 270, 318-323).

Compounds such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (Compound A, below) have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Compound A



2

There is thus a need for synthetic methods and intermediates useful in the preparation of Compound A and related compounds. It is, therefore, an object of the present application to provide such synthetic methods and intermediates.

SUMMARY

Provided herein are compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.


Provided is a process for making a compound of Formula I,



wherein Ar is an aryl such as phenyl, which aryl may be unsubstituted, or substituted 1-3 times, for example, with substituents independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, and halo C_{1-6} alkyl,

the method comprising one or more of the steps of:

- i) providing a composition comprising a compound of Formula II:



wherein Ar is as given above, and an organic solvent, wherein said composition is at a temperature of from -30 to 40°C ., or from -30 to 30°C ., or from -30 to 10°C ., or from -10 to 0°C ., or from -10 to -5°C .; and ii) adding to said composition a hydride reducing agent, wherein said agent reduces said compound of Formula II into said compound of Formula I, to thereby make said compound of Formula I.


In some embodiments, Ar is phenyl, which phenyl may be unsubstituted, or substituted 1-3 times with a halo independently selected from the group consisting of: chloro, fluoro, bromo, and iodo.

In some embodiments, the organic solvent is an aromatic hydrocarbon solvent, an aliphatic hydrocarbon solvent, a halogenated hydrocarbon solvent or an ether solvent.

In some embodiments, the process may further include the step of mixing (e.g., by stirring) the composition after said adding step for a time of 12 to 24 hours.

In some embodiments, the process may further include the step of quenching the reduction by adding to said composition a mild aqueous acid (e.g., citric acid, EDTA or tartaric acid).


In some embodiments, the compound of Formula II has the absolute stereochemistry of Formula IIa:



3

In some embodiments, the compound of Formula II has an enantiomeric excess (ee) of the Formula IIa stereoisomer of at least 75, 80, 85, 90, 95, 98, 99%, or greater.

In some embodiments, the compound of Formula II or Formula IIa is the compound:




In some embodiments, the compound of Formula I has the absolute stereochemistry of Formula Ia:



In some embodiments, the compound of Formula I has an enantiomeric excess (ee) of the Formula Ia stereoisomer of at least 75, 80, 85, 90, 95, 98, 99%, or greater.

In some embodiments, the compound of Formula I or Formula Ia is:




Also provided is compound of Formula III:



wherein Ar is an aryl such as phenyl, which aryl may be unsubstituted, or substituted 1-3 times, for example with substituents independently chosen from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkoxy, and haloC₁₋₆alkyl.

In some embodiments, Ar is phenyl, which phenyl may be unsubstituted, or substituted 1-3 times with a halo independently selected from the group consisting of: chloro, fluoro, bromo, and iodo.


In some embodiments, the compound is:



4

Also provided is a process for making a compound of Formula III:

5




III

10 wherein Ar is aryl such as phenyl, which aryl may be unsubstituted, or substituted 1-3 times, for example with substituents independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkoxy, and haloC₁₋₆alkyl,

15 comprising reacting a mixture of:

i) a compound of Formula Ia:

20



Ia

25

wherein Ar is as given above,

ii) vinyl acetate,

iii) a lipase, and

iv) an organic solvent

for a time of from 5 to 36 hours, or from 7 to 18 hours, 30 to thereby make the compound of Formula III.

In some embodiments, Ar is phenyl, which phenyl may be unsubstituted, or substituted 1-3 times with a halo independently selected from the group consisting of: chloro, fluoro, bromo, and iodo.

35 In some embodiments, the organic solvent is tetrahydrofuran, 2-methyltetrahydrofuran, an ether solvent, acetone, or acetonitrile.


In some embodiments, the lipase is a *Candida Antarctica* lipase, for example, a *Candida Antarctica* B lipase, which may be coupled to solid support such as an acrylic resin.

In some embodiments, the process may further include the step of filtering the mixture after said reacting to produce a filtrate, and may further include concentrating the filtrate to produce a concentrated filtrate. In some embodiments, the process may further include the step of washing the concentrated filtrate with water or water comprising a salt (e.g., a solution of 15-20% NaCl in water).

Also provided is a compound of Formula IV:

III

45



IV

wherein:

Ar is an aryl such as phenyl, which aryl may be unsubstituted, or substituted 1-3 times, for example with substituents independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkoxy, and haloC₁₋₆alkyl; and


R₁ is a leaving group.

55 In some embodiments, Ar is phenyl, which phenyl may be unsubstituted, or substituted 1-3 times with a halo independently selected from the group consisting of: chloro, fluoro, bromo, and iodo.


5

In some embodiments, the leaving group is a sulfonate ester leaving group selected from the group consisting of: mesylate, tosylate, nosylate, benzene sulfonate, and brosylate.

In some embodiments, the compound is:




In some embodiments, the compound of Formula IV has the absolute stereochemistry of Formula IVa:




In some embodiments, the compound of Formula IV has an enantiomeric excess (ee) of the Formula IVa stereoisomer of at least 75, 80, 85, 90, 95, 98, 99%, or greater.

Further provided is a process for making a compound of Formula IV:



wherein Ar is an aryl such as phenyl, which aryl may be unsubstituted, or substituted 1-3 times, for example with substituents independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkoxy, and haloC₁₋₆alkyl; and

R₁ is a sulfonate ester leaving group, said process comprising reacting a compound of Formula III:



wherein Ar is as given above, with a compound selected from the group consisting of: tosyl chloride, mesyl chloride, nosyl chloride, toluenesulfonyl chloride, toluenesulfonic anhydride and methanesulfonic anhydride, wherein said reacting is carried out in an organic solvent in the presence of a base


6

In some embodiments, Ar is phenyl, which phenyl may be unsubstituted, or substituted 1-3 times with a halo independently selected from the group consisting of: chloro, fluoro, bromo, and iodo.

5 In some embodiments, the reacting is carried out for a time of from 10 minutes to 2 hours.


In some embodiments, the base is an organic amine or potassium carbonate.

10 In some embodiments, the compound of Formula III is:



In some embodiments, the compound of Formula IV has the absolute stereochemistry of Formula IVa:

25 IVa



IVa


30 In some embodiments, the compound of Formula IV has an enantiomeric excess (ee) of the Formula IVa stereoisomer of at least 75, 80, 85, 90, 95, 98, 99%, or greater.

Also provided is a process for making a compound of Formula V,

35

V

IV 40



wherein Ar is an aryl such as phenyl, which aryl may be unsubstituted, or substituted 1-3 times, for example with substituents independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkoxy, and haloC₁₋₆alkyl; and

R₂ and R₃ are each independently selected from the group consisting of: hydrogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy, and hydroxyC₁₋₆alkyl,


comprising the steps of:

a) stirring a mixture of:

i) a compound of Formula IV:

60

IV



65

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.